Vunakizumab bests placebo in radiographic axial spondyloarthritis

Vunakizumab, a novel interleukin 17a monoclonal antibody, is superior to placebo in radiographic axial spondyloarthritis symptom improvement, according to data published in JAMA Network Open.
“Nonsteroidal anti-inflammatory drugs (NSAIDs) are the recommended first-line pharmacologic treatment for [radiographic axial SpA (r-axSpA)],” Jian Zhu, MD, of the Chinese People’s Liberation Army General Hospital, in Beijing, and colleagues wrote. “For persistently high disease activity despite NSAID treatment, biologic disease-modifying antirheumatic drugs (DMARDs) are subsequent treatment options.